BIOMAT Database Logo BIOMAT Database Logo

Phase II trial of bisantrene in patients with advanced sarcoma: a Southwest Oncology Group Study. 1986

J D Cowan, and E Gehan, and S E Rivkin, and S E Jones

UI MeSH Term Description Entries
D007022 Hypotension Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients. Blood Pressure, Low,Hypotension, Vascular,Low Blood Pressure,Vascular Hypotension
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000873 Anthracenes A group of compounds with three aromatic rings joined in linear arrangement.
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

J D Cowan, and E Gehan, and S E Rivkin, and S E Jones
Phase II trial of bisantrene in hepatocellular carcinoma: a Southwest Oncology Group Study.
November 1987, Cancer treatment reports,
J D Cowan, and E Gehan, and S E Rivkin, and S E Jones
Phase II trial of bisantrene in previously treated patients with ovarian carcinoma: a Southwest Oncology Group Study.
March 1986, Cancer treatment reports,
J D Cowan, and E Gehan, and S E Rivkin, and S E Jones
A phase II study of bisantrene in malignant lymphomas. A Southwest Oncology Group Study.
January 1986, Cancer chemotherapy and pharmacology,
J D Cowan, and E Gehan, and S E Rivkin, and S E Jones
Phase II evaluation of bisantrene in acute leukemia. A Southwest Oncology Group Study.
December 1989, American journal of clinical oncology,
J D Cowan, and E Gehan, and S E Rivkin, and S E Jones
Phase II evaluation of amonafide in advanced sarcoma: a Southwest Oncology Group study.
January 1994, Cancer investigation,
J D Cowan, and E Gehan, and S E Rivkin, and S E Jones
Phase II evaluation of bisantrene in refractory multiple myeloma. A Southwest Oncology Group study.
November 1991, Investigational new drugs,
J D Cowan, and E Gehan, and S E Rivkin, and S E Jones
Phase II trial of mitoxantrone in advanced sarcomas: a Southwest Oncology Group study.
February 1985, Cancer treatment reports,
J D Cowan, and E Gehan, and S E Rivkin, and S E Jones
Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study.
November 1992, Investigational new drugs,
J D Cowan, and E Gehan, and S E Rivkin, and S E Jones
Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study.
January 1987, Investigational new drugs,
J D Cowan, and E Gehan, and S E Rivkin, and S E Jones
Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
August 1991, Journal of the National Cancer Institute,
Copied contents to your clipboard!